FST and chronic kidney disease: Moreover, the treatment with activin A-binding protein, follistatin, or with RAP-011, a ligand trap of ActRllA, has revealed an amelioration of renal fibrosis and chronic kidney disease-mineral bone disorder (CKD-MBD) findings in CKD models [1, 33, 51, 73, 80].